Clinically significant (ie, active) cardiovascular disease: cerebral vascular accident/stroke (<6 months prior to enrollment), myocardial infarction (< 6 months prior to enrollment), unstable angina, congestive heart failure, or serious cardiac arrhythmia requiring medication.
Clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke (< 6 months prior to enrollment), myocardial infarction (< 6 months prior to enrollment), unstable angina, congestive heart failure (>= New York Heart Association Classification Class II), or serious cardiac arrhythmia requiring medication
Significant cardiovascular disease (New York Heart Association Class II or greater), myocardial infarction within the 6 months prior to study entry, unstable angina, or cerebral vascular accident / stroke (< 6 months prior to enrollment), or serious uncontrolled cardiac arrhythmia requiring medication / active intervention, corrected QT interval [QTc] prolongation of > 470ms and/or prior diagnosis of congenital long QT syndrome.
Uncontrolled or significant cardiovascular disease, including any of the following:\r\n* Symptomatic congestive heart failure (>= New York Heart Association Classification class II)\r\n* Cerebral vascular accident/stroke (< 6 months prior to enrollment), myocardial infarction (< 6 months prior to enrollment), or unstable angina\r\n* Uncontrolled hypertension or uncontrolled cardiac arrhythmia
PHASE II EXCLUSION CRITERIA: Uncontrolled or significant cardiovascular disease, including any of the following:\r\n* Symptomatic congestive heart failure (>= New York Heart Association Classification class II)\r\n* Cerebral vascular accident/stroke (< 6 months prior to enrollment), myocardial infarction (< 6 months prior to enrollment), or unstable angina\r\n* Uncontrolled hypertension or uncontrolled cardiac arrhythmia
Within 6 months prior to study drug administration, clinically significant cardiovascular/cerebrovascular disease defined as follows: cerebral vascular accident/stroke, myocardial infarction, unstable angina, congestive heart failure (New York Heart Association classification class >= II), bleeding or pulmonary embolism or cardiac arrhythmias that was severe enough to cause hemodynamic compromise
Clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke < 6 months prior to enrollment, myocardial infarction < 6 months prior to enrollment, unstable angina, congestive heart failure (>= New York Heart Association [NYHA] III) or serious cardiac arrhythmia requiring medication
Clinically significant cardiovascular/cerebrovascular disease as follows: cerebral vascular accident/stroke (< 6 months prior to enrollment), myocardial infarction (< 6 months prior to enrollment), unstable angina, congestive heart failure (New York Heart Association classification class > II), or serious cardiac arrhythmia.
Clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke (< 6 months prior to enrollment), myocardial infarction (< 6 months prior to enrollment), unstable angina, congestive heart failure (>= New York Heart Association classification class II), or serious cardiac arrhythmia requiring medication; patients with stable rate-controlled atrial fibrillation will be allowed to participate
Clinically significant cardiovascular/cerebrovascular disease as follows: cerebral vascular accident/stroke (< 6 months prior to enrollment), myocardial infarction (< 6 months prior to enrollment), unstable angina, congestive heart failure (New York Heart Association Classification class >= II), or serious cardiac arrhythmia
Clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke (< 6 months prior to enrollment), myocardial infarction (< 6 months prior to enrollment), unstable angina, congestive heart failure (>= New York Heart Association classification class II), or serious cardiac arrhythmia requiring medication
Clinically significant cardiovascular/ cerebrovascular disease as follows: cerebral vascular accident / stroke (< 6 months prior to enrollment), myocardial infarction (< 6 months prior to enrollment), unstable angina, congestive heart failure (New York Heart Association Classification class > II), or serious cardiac arrhythmia.
Clinically significant (i.e., active) cardiovascular disease: acute cerebral vascular accident/stroke (< 6 months prior to enrollment) excluding transient ischemic attack (TIA), myocardial infarction (< 6 months prior to enrollment), unstable angina, congestive heart failure (>= New York Heart Association classification class II), or serious cardiac arrhythmia requiring medication.
Clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident / stroke (< 6 months prior to enrollment), myocardial infarction (< 6 months prior to enrollment), unstable angina, congestive heart failure (>= New York Heart Association Classification class II), or serious cardiac arrhythmia requiring medication
Clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke (< 6 months prior to enrollment), myocardial infarction (< 6 months prior to enrollment), unstable angina, congestive heart failure (? New York Heart Association Classification class II), or serious cardiac arrhythmia requiring medication
Uncontrolled intercurrent illness including, but not limited to, clinically significant (i.e. active) cardiovascular disease: cerebral vascular accident/stroke (< 6 months prior to enrollment), myocardial infarction (< 6 months prior to enrollment), congestive heart failure (>= New York Heart Association [NYHA] class II), unstable angina pectoris, or serious cardiac arrhythmia requiring medication
Clinically significant cardiovascular / cerebrovascular disease as follows: cerebral vascular accident / stroke (< 6 months prior to enrollment), myocardial infarction (< 6 months prior to enrollment), unstable angina, congestive heart failure (New York Heart Association classification class >= II), serious cardiac arrhythmia, clinically significant bleeding or clinically significant pulmonary embolism
Clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke (< 6 months prior to enrollment), myocardial infarction (< 6 months prior to enrollment), unstable angina, congestive heart failure (>= New York Heart Association classification class II), or serious cardiac arrhythmia requiring medication.
Clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke (< 6 months prior to enrollment), myocardial infarction (< 6 months prior to enrollment), unstable angina, congestive heart failure (? New York Heart Association Classification class II), or serious cardiac arrhythmia requiring medication
Clinically significant (i.e. active) cardiovascular disease: cerebral vascular accident (< 6 months prior to enrollment), myocardial infarction (< 6 months prior to enrollment), unstable angina, congestive heart failure (>= New York Heart Association Classification class II), or serious cardiac arrhythmia requiring medication
Clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke (< 6 months prior to enrollment), myocardial infarction (< 6 months prior to enrollment), unstable angina, congestive heart failure (>= New York Heart Association classification class II), or serious cardiac arrhythmia requiring medication
Clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke (< 6 months prior to enrollment), myocardial infarction (< 6 months prior to enrollment), unstable angina, congestive heart failure (>= New York Heart Association Classification class II), or serious cardiac arrhythmia requiring medication
Clinically significant cardiovascular disease including cerebral vascular accident/stroke (< 6 months prior to enrollment), myocardial infarction (< 6 months prior to enrollment), congestive heart failure with New York Heart Association (NYHA) class II or greater or serious cardiac arrhythmia requiring medication
Clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke (< 6 months prior to enrollment), myocardial infarction (< 6 months prior to enrollment), unstable angina, congestive heart failure (>= New York Heart Association Classification class II), or serious cardiac arrhythmia requiring medication
Clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke (< 6 months prior to enrollment), myocardial infarction (< 6 months prior to enrollment), unstable angina, congestive heart failure (>= New York Heart Association Classification class II), or serious cardiac arrhythmia requiring medication
Clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke (< 6 months prior to enrollment), myocardial infarction (< 6 months prior to enrollment), unstable angina, congestive heart failure (New York Heart Association [NYHA] class >= II), or serious uncontrolled cardiac arrhythmia
Clinically significant (active) cardiovascular disease: cerebral vascular accident/stroke or myocardial infarction within 6 months prior to study enrollment; unstable angina, congestive heart failure or a serious cardiac arrhythmia requiring medication.
Clinically significant (that is, active) cardiovascular disease: cerebral vascular accident / stroke (< 6 months prior to enrollment), myocardial infarction (< 6 months prior to enrollment), unstable angina, congestive heart failure (New York Heart Association Classification Class >= II), or serious cardiac arrhythmia requiring medication
Clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke (< 6 months prior to enrollment), myocardial infarction (< 6 months prior to enrollment), unstable angina, congestive heart failure (>= New York Heart Association Classification class II), or serious cardiac arrhythmia requiring medication
Clinically significant cardiovascular disease: cerebral vascular accident/stroke or myocardial infarction within 6 months prior to study entry; unstable angina, congestive heart failure or a serious cardiac arrhythmia requiring medication.
Uncontrolled intercurrent illness including, but not limited to: ongoing or active infection requiring systemic therapy, clinically significant cardiovascular disease including: cerebral vascular accident/stroke (< 6 months prior to enrollment), myocardial infarction (< 6 months prior to enrollment), unstable angina, congestive heart failure (>= New York Heart Association Classification class II), or serious cardiac arrhythmia requiring medication, uncontrolled diabetes mellitus, or psychiatric illness/social situations that would limit compliance with study requirements; ability to comply with study requirements is to be assessed by each investigator at the time of screening for study participation
Clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke (<6 months before enrollment), myocardial infarction (<6 months before enrollment), unstable angina, congestive heart failure (New York Heart Association class ?II), or serious uncontrolled cardiac arrhythmia requiring medication.
Clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke (< 6 months prior to enrollment), myocardial infarction (< 6 months prior to enrollment), unstable angina, congestive heart failure (>= New York Heart Association Classification class II), or serious cardiac arrhythmia requiring medication
Clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke (< 6 months prior to enrollment), myocardial infarction (< 6 months prior to enrollment), unstable angina, congestive heart failure (>= New York Heart Association Classification class II), or serious cardiac arrhythmia requiring medication
Clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke (< 6 months prior to enrollment), myocardial infarction (< 6 months prior to enrollment), unstable angina, congestive heart failure (>= New York Heart Association classification class II), or serious cardiac arrhythmia requiring medication
Patients with a history of stroke or intracranial hemorrhage within 6 months prior to registration are not eligible
History of stroke or intracranial hemorrhage within 6 months prior to enrollment
History of stroke or intracranial hemorrhage within 6 months prior to enrollment
No active intracranial metastases
History of stroke/intracranial hemorrhage =< 6 months prior to registration
History of stroke or intracranial hemorrhage within 6 months prior to randomization
History of stroke or intracranial hemorrhage within 6 months of first dose
Intracranial hemorrhage grade > 1 not attributable to recent neurosurgery
History of stroke or intracranial hemorrhage within 6 months prior to enrollment
Any history of symptomatic intracranial hemorrhage.
Patients should not have a stroke or intracranial hemorrhage within last 6 months
Patients will not be eligible if they have a history of intracranial hemorrhage in past 6 months
History of stroke or intracranial hemorrhage within 6 months prior to enrollment
History of ischemic stroke or intracranial hemorrhage =< 180 days prior to pre-registration
History of stroke/intracranial hemorrhage =< 6 months prior to registration
History of stroke or intracranial hemorrhage within 6 months prior to enrollment
History of stroke or intracranial hemorrhage within 6 months of the first dose of study drug
History of stroke or intracranial hemorrhage within 6 months prior to enrollment
History of stroke or intracranial hemorrhage within 6 months before the first dose of study drug
History of stroke or intracranial hemorrhage within 6 months prior to enrollment
History of stroke or intracranial hemorrhage within 6 months prior to enrollment
History of stroke or intracranial hemorrhage within 6 months prior to enrollment
Evidence of acute intracranial / intra-tumoral hemorrhage, except for participants with stable grade 1 hemorrhage.
History of stroke or intracranial hemorrhage within 6 months prior to enrollment
History of stroke or intracranial hemorrhage within 6 months prior to randomization
Intracranial hemorrhage except for tumor associated micro hemorrhage.
History of stroke or intracranial hemorrhage within 6 months prior to study entry
History of intracranial hemorrhage (either by clinical history or neuroimaging)
History of stroke or intracranial hemorrhage within 6 months of screening
No history of intracranial hemorrhage
Relapsed/refractory MCL: History of stroke or intracranial hemorrhage within 6 months prior to signing the consent
Newly diagnosed MCL: History of stroke or intracranial hemorrhage within 6 months prior to signing the consent
Evidence of recent (less than 2 weeks) intracranial hemorrhage.
Have evidence of significant (ie, symptomatic) intracranial hemorrhage.
History of stroke or intracranial hemorrhage within 6 months prior to enrollment
History of stroke or intracranial hemorrhage within 6 months prior to enrolment
History of stroke or intracranial hemorrhage within 3 months prior to enrollment
History of stroke or intracranial hemorrhage within 6 months prior to signing the consent.
History of stroke or intracranial hemorrhage within 6 months prior to enrollment
History of stroke or intracranial hemorrhage within 6 months prior to enrollment
History of stroke or intracranial hemorrhage within 6 months before randomization.
History of stroke or intracranial hemorrhage within 6 months before randomization.
history of stroke or intracranial hemorrhage within 6 months prior to enrollment
History of stroke or clinically significant intracranial hemorrhage within 6 months before first dose of study drug.
History of stroke or intracranial hemorrhage within 6 months prior to enrollment
No stroke or intracranial hemorrhage within the last 6 months
History of stroke or intracranial hemorrhage within 6 months prior to enrollment
History of stroke or intracranial hemorrhage within 6 months prior to enrollment
History of stroke or intracranial hemorrhage within 6 months prior to enrollment.
History of stroke or intracranial hemorrhage within 6 months prior to enrollment
Patient has history of stroke or intracranial hemorrhage =< 6 months from starting study drugs
History of stroke or intracranial hemorrhage within 6 months prior to enrollment
History of stroke or intracranial hemorrhage within 6 months prior to the first dose of study drug
History of stroke or intracranial hemorrhage within 6 months prior to enrollment
History of stroke or intracranial hemorrhage within 6 months prior to study entry
Active intracranial hemorrhage
History of stroke or intracranial hemorrhage within 6 months prior to the first dose of ibrutinib
History of stroke or intracranial hemorrhage within 6 months prior to enrollment.
History of stroke or intracranial hemorrhage within 12 months prior to enrollment.
Subjects with a history of stroke or intracranial hemorrhage within 6 months prior to enrollment are not eligible
History of stroke or intracranial hemorrhage within 6 months prior to randomization
History of stroke or intracranial hemorrhage within 6 months prior to enrollment
History of stroke or intracranial hemorrhage within 6 months prior to random assignment
History of Grade 2 (CTCAE v4) or greater acute intracranial hemorrhage.
History of stroke or intracranial hemorrhage within 6 months prior to randomization; or clinically significant cardiovascular disease
History of stroke or intracranial hemorrhage within 6 months prior to enrollment
History of stroke or intracranial hemorrhage within 6 months of screening would be exclusion for ibrutinib therapy but idelalisib would be an option
History of stroke or intracranial hemorrhage within 6 months prior to registration
History of stroke or intracranial hemorrhage within 6 months prior to enrollment
Patients with a history of known stroke or intracranial hemorrhage within 6 months prior to study treatment are excluded
History of stroke or intracranial hemorrhage within 6 months prior to enrollment.
History of stroke or intracranial hemorrhage within 6 months prior to enrollment
History of stroke or intracranial hemorrhage within 6 months prior to enrollment
Patients with a history of intracranial hemorrhage are not eligible.
History of stroke or intracranial hemorrhage =< 6 months prior to registration
History of stroke or intracranial hemorrhage within 6 months prior to treatment
Evidence of significant intracranial hemorrhage
History of stroke or intracranial hemorrhage within 6 months of enrollment
History of stroke or intracranial hemorrhage within 6 months prior to enrollment
History of stroke or intracranial hemorrhage within 6 months prior to enrollment
Diagnosis of intracranial hemorrhage within the past 3 months, including intratumoral hemorrhage into brain metastases from a systemic cancer
Any history of significant hemorrhage (requiring hospitalization or transfusion) within the last 6 months (excluding hemorrhage during operative procedure)
EXCLUSION CRITERIA (PRIOR TO IBRUTINIB ADMINISTRATION): History of stroke or intracranial hemorrhage within 6 months prior to screening
Patients must not have evidence of significant intracranial hemorrhage
History of stroke or intracranial hemorrhage within 6 months prior to enrollment
No hemorrhage after treatment.
History of stroke or intracranial hemorrhage within 6 months of first dose
No history of any prior stroke (hemorrhagic or ischemic)
History of stroke within 6 months.
Stroke.
Known history of stroke or cerebrovascular accident within 6 months before enrollment.
Any history of hemorrhagic stroke
History or evidence of central nervous system bleeding as defined by stroke or intraocular bleed (including embolic stroke) not associated with any antitumor surgery within 6 months before enrolment
Stroke, serious cardiac arrhythmia within the 6 months prior to study drug administration
History of ischemic stroke within 6 months prior to enrollment.
History of hemorrhagic or ischemic stroke within the last 6 months
Previous stroke < 12 months
History of stroke within the last 5-years
History of stroke or cerebral hemorrhage within 2 months
History of central nervous system bleeding as defined by stroke or intraocular bleed within 6 months of enrollment.
History of stroke or cerebral hemorrhage within 6 months
History of stroke or cerebral hemorrhage within 2 month
Patient with stroke in the last 3 months
History of stroke within 6 months
History of stroke within 6 months
History (within the last 3 months) or presence of stroke/cerebrovascular accident
TIA or stroke in the last 1 month.
TIA or stroke in the last 1 month
History of stroke within six months
History of cerebral vascular accident or stroke within the previous 2 years
Known history of stroke or cerebrovascular accident within 6 months prior to enrollment
History of thrombotic or hemorrhagic stroke or myocardial infarction within 6 months.
Stroke or other symptoms of cerebral vascular insufficiency within the last 3 months.
History of stroke or cerebral hemorrhage within 6 months
Known history of stroke or cerebrovascular accident within 6 months prior to enrollment
Known history of stroke or cerebrovascular accident within 6 months prior to enrollment
History of stroke or cerebral hemorrhage within 2 months
Known history of stroke or cerebrovascular accident within 6 months prior to the first dose of study drug
PART B: Any history of myocardial infarction or embolic/occlusive cerebro-vascular accident (stroke)
History of stroke within 6 months prior to study registration
History of stroke within 6 months of registration
History of stroke within 6 months prior to day 1
History of stroke
Known history of stroke or cerebrovascular accident within 6 months prior to the first dose of protocol therapy.
Known history of stroke or cerebrovascular accident within 6 months prior to the first dose of study drug.
5. Known history of stroke or cerebrovascular accident within 6 months prior to the first dose of study drug.
Known history of stroke or cerebrovascular accident within 6 months.
History of stroke within 6 months
History of hemorrhagic or ischemic stroke within 6 months prior to first dose of mirvetuximab soravtansine
Hemorrhagic, embolic, or thrombotic stroke within 6 months of scheduled dosing day 1;
History of stroke within 6 months prior to study enrollment.
History of a prior symptomatic stroke, dementia, or other significant central neurologic condition (i.e. multiple sclerosis)
History of stroke within six months
History (within the last 6 months) or presence of stroke/cerebrovascular accident
History of stroke or cerebral hemorrhage within 2 months
EXCLUSION - STUDY 1: Stroke
Stroke within the past 2 years
History of stroke
No history of hemorrhagic stroke
stroke (within the last 6 month)
History of bleeding disorder or hemorrhagic stroke
Stroke in the last six months
History of severe brain-injury or stroke.
History of bleeding disorder or hemorrhagic stroke
History of cerebrovascular accident (stroke)
Stroke or TIA within 12 last months
History of stroke with the past year
History of thrombotic or hemorrhagic stroke or myocardial infarction within 6 months
Subjects with history or evidence upon physical examination of central nervous system (CNS) disease, including primary brain tumor, seizures not controlled with standard medical therapy, any brain metastases, or, within 6 months of the first date of treatment on this study, history of cerebrovascular accident (CVA, stroke), transient ischemic attack (TIA) or subarachnoid hemorrhage.
Patients with history or evidence upon physical examination of central nervous system (CNS) disease; seizures not controlled with standard medical therapy; any brain metastases; or history of cerebral vascular accident (CVA), transient ischemic attack (TIA), or subarachnoid hemorrhage within 6 months of the first date of treatment on this study; patients diagnosed with primary brain tumors within the last three years are also excluded
Patients with history of cerebrovascular accident (CVA, stroke), transient ischemic attack (TIA) or subarachnoid hemorrhage within 6 months of the first date of treatment on this study
Patients with history or evidence upon physical examination of central nervous system (CNS) disease, including primary brain tumor, seizures which are not controlled with non-enzyme inducing anticonvulsants, any brain metastases and/or epidural disease, or history of cerebrovascular accident (CVA, stroke), transient ischemic attack (TIA) or subarachnoid hemorrhage within six months prior to the first date of study treatment
Patients with history of cerebrovascular accident (CVA, stroke), transient ischemic attack (TIA) or subarachnoid hemorrhage within six months of the first date of treatment on this study are ineligible
History or evidence upon physical examination of central nervous system (CNS) disease, including primary brain tumor, any brain metastases, or history of cerebrovascular accident (CVA, stroke), transient ischemic attack (TIA) within 6 months of Cycle 1 Day
This criterion applies only to the patients enrolled before August 29, 2011 and those enrolled after this date electing to receive bevacizumab; patients with a history or evidence upon physical examination of central nervous system (CNS) disease, including primary brain tumor, seizures not controlled with standard medical therapy, any brain metastases or a history of stroke within 5 years of the first date of treatment on this study
Patients with history or evidence upon physical examination of CNS disease, including primary brain tumor, seizures not controlled with standard medical therapy, any brain metastases, or history of cerebrovascular accident (CVA, stroke), transient ischemic attack (TIA) or subarachnoid hemorrhage within six months of the first dose of study drug.
History or evidence upon physical examination of central nervous system (CNS) disease, including primary brain tumor, seizures which are not controlled with non-enzyme inducing anticonvulsants, any brain metastases and/or epidural disease, or history of cerebrovascular accident (cerebrovascular accident [CVA], stroke), transient ischemic attack (TIA) or subarachnoid hemorrhage within six months prior to the first date of study treatment
Patients with history or evidence upon physical examination of CNS disease, including primary brain tumor, seizures not controlled with standard medical therapy, any brain metastases, or history of cerebrovascular accident (CVA, stroke), transient ischemic attack (TIA) or subarachnoid hemorrhage within six months of the first date of treatment on this study.
Subjects with history or evidence upon physical examination of CNS disease, including primary brain tumor, seizures not controlled with standard medical therapy, any brain metastases, or, within six months prior to Day 1 of this study, history of cerebrovascular accident (CVA, stroke), transient ischemic attack (TIA) or subarachnoid hemorrhage.
Patients with history or evidence upon physical examination of central nervous system (CNS) disease, including primary brain tumor, seizures not controlled with standard medical therapy, any brain metastases, or history of cerebrovascular accident (CVA, stroke), transient ischemic attack (TIA) or subarachnoid hemorrhage within 6 months of the first date of treatment on this study
Patients with history or evidence upon physical examination of central nervous system (CNS) disease, including primary brain tumor, seizures which are not controlled, any brain metastases and/or epidural disease, or history of cerebrovascular accident (CVA, stroke) within six months prior to the first date of study treatment
Patients with history or evidence upon physical examination of central nervous system (CNS) disease, including primary brain tumor, seizures not controlled with standard medical therapy, any brain metastases, or history of cerebrovascular accident (CVA, stroke), transient ischemic attack (TIA) or subarachnoid hemorrhage within six months of the first date of treatment on this study
Patients with history or evidence upon physical examination of CNS disease, including primary brain tumor, seizures not controlled with standard medical therapy, any brain metastases, or history of cerebrovascular accident (CVA, stroke), transient ischemic attack (TIA) or subarachnoid hemorrhage within six months of the first date of treatment on this study.
Any known history of cerebrovascular disease including TIA, stroke or subarachnoid hemorrhage
Subjects with history of evidence upon physical examination of central nervous system (CNS) disease including primary brain tumor, seizures not controlled with standard medical therapy, any brain metastases, or history of cerebrovascular accident (CVA, stroke), transient ischemic attack (TIA), or subarachnoid hemorrhage within six months of study entry
Subjects with a history of evidence upon physical examination of central nervous system (CNS) disease including primary brain tumor, seizures not controlled with standard medical therapy, any brain metastases, or history of cerebrovascular accident (CVA, stroke), transient ischemic attack (TIA), or subarachnoid hemorrhage within six months of study entry
